Approval based on DUO-E trial results, which showed IMFINZI reduced the risk of disease progression or death by 58% vs. chemotherapy WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s IMFINZI® ...

Please provide your email address to receive an email when new articles are posted on . Patients with stage III deficient mismatch repair colon cancer derived significant benefit from the addition of ...

Please provide your email address to receive an email when new articles are posted on . Results showed a DFS benefit with the addition of pembrolizumab to chemotherapy for patients with mismatch ...

Systemic Therapy for Muscle-Invasive Urothelial Carcinoma of the Bladder (Muscle-Invasive Bladder Cancer): Insights From Real-World Data Patients with stage I-III colon cancer treated with upfront ...

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01) The National Cancer Institute ...

Patients with mismatch repair deficient gastric cancer demonstrated better median overall survival when skipping perioperative chemotherapy, according to a preprint study. Median overall survival is ...

Colon cancer is the third most prevalent form of cancer in the U.S., and its incidence is increasing among younger adults, particularly those younger than 50. While colon cancer screening has helped ...

Neoadjuvant PD-1 blockade with dostarlimab enables nonoperative management strategy for large proportion of patients. HealthDay News — A neoadjuvant programmed cell death 1 (PD-1) blockade enables ...

Two new immunotherapy-chemotherapy options are now approved for patients with primary advanced or recurrent endometrial cancer, the FDA announced. On Monday, the agency approved the PD-1-directed ...

Researchers have uncovered the mechanisms behind three unique subtypes of mismatch repair deficient high-grade gliomas. The findings provide a clearer understanding of how these tumors develop, ...